LifeMD, Inc.
LifeMD, Inc.
Join ActionIf you are a LifeMD investor who suffered a loss and would like to learn more, you can provide your information below:
If you suffered losses in LifeMD between May 7, 2025 and August 5, 2025, both dates inclusive (the “Class Period”) Securities Litigation Partner James (Josh) Wilson encourages you to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) or you can submit your information below.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) and reminds investors of the October 27, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
CASE DETAILS: As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants materially overstated LifeMD’s competitive position; (2) Defendants were reckless in raising LifeMD’s 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD’s RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound; and (3) as a result, Defendants’ statements about LifeMD’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
STOCK DROP: On August 5, 2025, after markets closed, LifeMD reported its second-quarter 2025 results and lowered its full-year revenue forecast to $250–$255 million, down from its earlier guidance of $268–$275 million. The next day, the stock plunged 44.8%.
WHAT’S NEXT? If you incurred a loss in LifeMD during the class period, you have until the October 27, 2025 deadline, to petition the Court for appointment as lead plaintiff.The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding LifeMD’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
